Protein kinase A-Iα subunit-directed antisense inhibition of ovarian cancer cell growth: Crosstalk with tyrosine kinase signaling pathway

Oncogene

Volumn 18, Issue 35, 1999, Pages 4999-5004

  Alper, Özge ^a,c   Hacker, Neville F ^b   Cho Chung, Yoon S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROYAL HOSPITAL FOR WOMEN   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Antisense; EGF receptor; Ovarian cancer; Protein kinase A; Tyrosine kinase

Indexed keywords

COMPLEMENTARY DNA; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ISOENZYME; MESSENGER RNA; ONCOPROTEIN; PROTEIN KINASE (CALCIUM,CALMODULIN); REGULATORY SUBUNIT RIALPHA, CYCLIC AMP DEPENDENT PROTEIN KINASE; REGULATORY SUBUNIT RIALPHA, CYCLIC-AMP-DEPENDENT PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL NUCLEUS; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBUNIT; FEMALE; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; ONCOGENE C ERB; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL CULTURE; CELL DIVISION; CELL SIZE; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY;

APOPTOSIS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL DIVISION; CELL SIZE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOWN-REGULATION; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; ISOENZYMES; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033517254     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1202830     Document Type: Article

References (35)

1. Aaronson SA. (1991). Science, 254, 1146-1153.
2. Alper Ö, Agrawal S and Cho-Chung YS. (1998). Proc. Am. Assoc. Cancer Res., 39, 646.
3. Beebe SJ and Corbin JD. (1986). In: The Enzymes: Control by Phosphorylation, Part A, vol. 17. Boyer PD and Krebs EG (eds). Academic Press: New York, pp. 43-111.
4. Budillon A, Cereseto A, Kondrashin A, Nesterova M, Merlo G, Clair T and Cho-Chung YS. (1995). Proc. Natl. Acad. Sci. USA, 92, 10634-10638.
5. Chen J and Iyengar R. (1994). Science, 263, 1278-1281.
6. Cho-Chung YS, Clair T, Tagliaferri P, Ally S, Katsaros D, Tortora G, Neckers L, Avery TL, Crabtree GW and Robins RK. (1989). Cancer Invest., 7, 161-177.
7. Cho-Chung YS, Nesterova M, Kondrashin A, Noguchi K, Srivastava R and Pepe S. (1997). Antisense Nucl. Acid Drug Dev., 7, 217-223.
8. Cho-Chung YS. (1990). Cancer Res. [Perspectives in Cancer Research] . 50, 7093-7100.
9. Cho-Chung YS. (1996). Antisense Nucl. Acid Drug Dev., 6, 237-244.
10. Ciardiello F, Tortora G, Kim N, Clair T, Ally S, Salomon DS and Cho-Chung YS. (1990). J. Biol. Chem., 265, 1016-1020.
11. Ciardiello F, Dixit M, di Isernia G, Damiano V, Bianco R, Bianco AR, Arteaga CL and Tortora G. (1998). Br. Cancer Res. Treat., 47, 57-62.
12. Cobb CE, Beth AH and Corbin JD. (1987). J. Biol. Chem., 262, 16566-16574.
13. Cook SJ and McCormick F. (1993). Science, 262, 1069-1072.
14. Davis RJ. (1993). J. Biol. Chem., 268, 14553-14556.
15. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M and Fabbro D. (1996). Cancer Res., 56, 3499-3507.
16. Guyton KZ, Gorospe M, Kensler TW and Holbrook NJ. (1996). Cancer Res., 56, 3480-3485.
17. Krebs EG and Beavo JA. (1979). Annu. Rev. Biochem., 48, 923-939.
18. Levy FO, Oyen O, Sandberg M, Tasken K, Eskild W, Hansson V and Jahnsen T. (1988). Mol. Endocrinol., 2, 1364-1373.
19. Lohmann SM and Walter U. (1984). In: Advances in Cyclic Nucleotide and Protein Phosphorylation Research, vol. 18. Greengard P and Robison GA (eds). Raven Press: New York, pp. 63-117.
20. McKnight GS, Clegg CH, Uhler MD, Chrivia JC, Cadd GG, Correll LA and Otten AD. (1988). Recent Prog. Horm. Res., 44, 307-335.
21. Metelev V, Lisziewicx J and Agrawal S. (1994). Bioorganic Med. Chem. Lett., 4, 2929-2934.
22. Monia BP, Johnston JF, Geiger T, Muller M and Fabbro D. (1996). Nature Med., 2, 668-675.
23. Nesterova M and Cho-Chung YS. (1995). Nature Med., 1, 528-533.
24. Nesterova M, Yokozaki H, McDuffie E and Cho-Chung YS. (1996). Eur. J. Biochem., 253, 486-494.
25. Otten AD, Parenteau LA, Doskeland S and McKnight GS. (1991). J. Biol. Chem., 266, 23074-23082.
26. Pegues JC and Stromberg K. (1997). Cancer Lett., 117, 73-79.
27. Schwartz DA and Rubin CS. (1985). J. Biol. Chem., 260, 6296-6303.
28. Srivastava RK, Srivastava AR, Park YG, Agrawal S and Cho-Chung YS. (1998). Breast Cancer Res. Treat., 49, 97-107.
29. Stein CA. (1995). Nature Med., 1, 1119-1121.
30. Sturgill TW, Ray LB, Erikson F. and Maller JL. (1988). Nature (Lond.), 334, 715-718.
31. Tortora G, Ciardiello F, Ally S, Clair T, Salomon DS and Cho-Chung YS. (1989). FEBS Lett., 242, 363-367.
32. Tortora G, Yokozaki H, Pepe S, Claire T and Cho-Chung YS. (1991). Proc. Natl. Acad. Sci. USA, 88, 2011-2015.
33. Tortora G, Damiano V, Bianco C, Baldassarre G, Bianco AR, Lanfrancone L, Pelicci PG and Ciardiello F. (1997). Oncogene, 14, 923-928.
34. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ and Sturgill TW. (1993). Science, 262, 1065-1068.
35. Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage SL, Miki K and Cho-Chung YS. (1993). Cancer Res., 53, 868-872.